Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
出版年份 2018 全文链接
标题
Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
作者
关键词
Severe eosinophilic asthma, Mepolizumab, Treatment response, IL-5, Lung function
出版物
BMC Pulmonary Medicine
Volume 18, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-07-19
DOI
10.1186/s12890-018-0689-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
- (2018) Manali Mukherjee et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Associations between blood eosinophils and decline in lung function among adults with and without asthma
- (2018) Robert J. Hancox et al. EUROPEAN RESPIRATORY JOURNAL
- The construction and validation of the Severe Asthma Questionnaire
- (2018) Michael E. Hyland et al. EUROPEAN RESPIRATORY JOURNAL
- Oral corticosteroid exposure and adverse effects in asthmatic patients
- (2018) Patrick W. Sullivan et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
- (2018) J Mark FitzGerald et al. Lancet Respiratory Medicine
- Biomarkers for severe eosinophilic asthma
- (2017) Steven W. Yancey et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Seasonal and geographic variations in the incidence of asthma exacerbations in the United States
- (2017) M. Gerhardsson de Verdier et al. JOURNAL OF ASTHMA
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe and Difficult-to-Treat Asthma in Adults
- (2017) Elliot Israel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of New Therapies for Severe Asthma
- (2017) Merritt L. Fajt et al. Allergy Asthma & Immunology Research
- Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype
- (2017) Anirban Basu et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
- (2017) Geoffrey L Chupp et al. Lancet Respiratory Medicine
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
- (2016) Hector G Ortega et al. Lancet Respiratory Medicine
- The prevalence of severe refractory asthma
- (2015) Pieter-Paul W. Hekking et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
- (2015) David B Price et al. Lancet Respiratory Medicine
- Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
- (2014) Pranabashis Haldar et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales
- (2014) Michael E. Hyland et al. QUALITY OF LIFE RESEARCH
- Impact of Asthma Exacerbations and Asthma Triggers on Asthma-related Quality of Life in Patients with Severe or Difficult-to-Treat Asthma
- (2014) Allan T. Luskin et al. Journal of Allergy and Clinical Immunology-In Practice
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- Global asthma prevalence in adults: findings from the cross-sectional world health survey
- (2012) Teresa To et al. BMC PUBLIC HEALTH
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
- (2012) Philip H. Quanjer et al. EUROPEAN RESPIRATORY JOURNAL
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria
- (2011) Stephanie Korn et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
- (2009) Prescott G. Woodruff et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels
- (2008) Miguel L. Stein et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Use of a preference-based measure of health (EQ-5D) in COPD and asthma
- (2008) A. Simon Pickard et al. RESPIRATORY MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started